Reuters reports that the U.S. Senate has joined in the battle over CMS guidelines and how they are affecting both Amgen and the doctors that Amgen reimburses. On Tuesday, September 4, 2007, the U.S. Senate “passed a nonbinding resolution urging [CMS] to immediately reconsider payment limits for use of anemia drugs by elderly and disabled people with cancer. This move by the government positively affects Amgen and its shareholders as its shares have recently risen. Amgen continues to step up its lobbying efforts with the help of U.S. cancer doctors. Bear in mind, however, what reconsideration of the guidelines could mean for the patients who will be affected by the drugs.

Reuters: “Amgen Shares Up As Lawmakers Enter Anemia Drug Row”

Related Articles:

CNNMoney.com: “Amgen Stock Rises on Senate Move”

Los Angeles Times: “Senators Aid Amgen’s Claim with Medicare”